STAT

Congress isn’t acting to curb drug prices, so states are stepping up. Here’s how

With little action in Congress, states from California to Vermont are experimenting with ways to try to curb drug prices or shine a light on rising costs.

President Trump has complained that drug makers are getting away with murder — and he may be right.

Despite vociferous complaints from consumers that drug prices are too high, Congress has failed to act. And with few exceptions, the pharmaceutical industry has successfully delayed or thwarted state bills that would force drug makers to explain or justify price hikes.

But that may be starting to change. Last week, of the pharma industry, already has a similar policy in place.  recently began requiring drug makers to disclose pricing data about diabetes medicines. And has a new law that penalizes generic companies for price gouging.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks